Finzati - Logo
UTHR logo

United Therapeutics Corporation

UTHR • Biotechnology
$487.61
▼ -2.63 (-0.54%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$22.33B
Growth
41.6%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 41.9%Positive revenue growth · 17.6%Positive free cash flow · 23.49Consistent free cash flow · 5/5Reasonable earnings multiple · 16.17
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:23 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$487.61
Change-0.54%
Shares Out45.80M
Market Cap$22.33B
Enterprise Value$20.53B
52W Range292.34 - 609.35
Beta0.58
P/E17.04
P/S7.08
P/B3.49
P/FCF20.43
EV/Sales6.51

Investment DNA

How strong this company looks for long-term investors

88
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
70/100
Why this score▼
Stable or improving margins · 41.9%Positive revenue growth · 17.6%Positive free cash flow · 23.49Consistent free cash flow · 5/5Reasonable earnings multiple · 16.17Manageable debt level · 0

Analyst view

Analyst sentiment and price target

UTHR
Analyst sentiment
Based on 30 analyst votes · 2026-09-05
75/100
Bullish
Bullish
16
Hold
13
Bearish
1
Price Target
2026-08-07
Low
$515.00
Mean
$635.00
Median
$625.00
High
$735.00

Company Overview

IPO: 6/17/1999
Industry: Biotechnology
P/B i: 3.49
Debt / Equity i: 0.00
Operating Margin: 47.67%
Net Margin: 41.94%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.00
Current Ratio: 6.60
Quick Ratio: 6.28
Status: Strong

Insider Transactions

Recent executive and insider activity

ROTHBLATT MARTINE A
Transaction: 08/04/2026
SELL
Change
-9,500
Price
$135.42
Filing
08/05/2026
Type
SELL
ROTHBLATT MARTINE A
Transaction: 08/04/2026
SELL
Change
-299
Price
$520.49
Filing
08/05/2026
Type
SELL
ROTHBLATT MARTINE A
Transaction: 08/03/2026
SELL
Change
-9,500
Price
$135.42
Filing
08/04/2026
Type
SELL